Sales in Q3 came in lower than expected, but sales related to warm perfusion were in line with our forecast and saw continued strong growth. The gross margin for non-durable goods was in line with our expectations, but slightly higher-than-expected operating expenses and depreciation resulted in an EBIT margin below our forecast. Overall, we keep a positive view on the report, focusing on the strong result for sales related to warm perfusion. We will return with an updated analysis shortly.